1-3 of 3
Shelonitda Rose
Close
Sort by
Journal Articles

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Clinical Trials & Observations
Aaron T. Gerds, Claire N. Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Maria Vannucchi, Rami S Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Shelonitda Rose, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, MD, Huijing Jiang, Jeanne M Palmer, Kelly McCaul, Vincent Ribrag, Francesco Passamonti
Journal: Blood Advances
Blood Adv bloodadvances.2024012939.
https://doi.org/10.1182/bloodadvances.2024012939
Published: 2024
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2219–2229.
https://doi.org/10.1182/bloodadvances.2021006138
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Ken Ogasawara, James Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2207–2218.
https://doi.org/10.1182/bloodadvances.2021005487
Published: 2022
Includes: Supplemental data